Published final results of the DeCOG-SLT trial add evidence that patients who have a positive sentinel lymph-node biopsy, and have immediate complete lymph node dissection, do not achieve…
A preliminary clinical study looking at previously untreated metastatic melanoma showed promising results when treating with the combination of an IL-2 signaling agonist and nivolumab. Primary trial objectives…
Benjamin Prince, MD, MSCI, FAAAAI, allergist/immunologist at Nationwide Children’s Hospital in Columbus, Ohio, discusses primary immunodeficiency diseases. Many patients have a genetic defect that results in part of…
Despite an abundance of preclinical evidence supporting the treatment strategy of combining an IDO1 inhibitor with anti-PD-1/PD-L1 immunotherapy, the results of a recent clinical trial were unable to confirm…
In this video, Dr. Daniel George, MD, discusses the results of a sunitinib study that helped change the treatment landscape for renal cell carcinoma (RCC). Compared to placebo,…
Results from the CARMENA trial, presented at the 2019 annual meeting of the American Society of Clinical Oncology suggest that cytoreductive nephrectomy should no longer be considered the…
Findings from a planned sub-analysis of clinical trial data comparing treatment options for renal cell carcinoma patients (RCC) with sacromatoid history were presented at the 2019 American Society…
The US Food and Drug Administration (FDA) has approved the immunotherapy avelumab in combination with the tyrosine kinase inhibitor axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The…
According to the Associated Press’ search of a U.S. government database, six of the eight currently registered clinical trials studying deep brain stimulation (DBS) for addiction treatment are…
F. Perry Wilson, MD, MSCE, shares insights from a review of recent study results published in the New England Journal of Medicine examining duty-hours rules at 63 residency…
